Oncolytic-adenovirus-expressed RNA interference for cancer therapy

Bibliography

• Bass BL. Double-stranded RNA as a template for gene silencing. Cell 2000;28:235-8
   Google Scholar
• Hammond SM, Caudy AA, Hannon GJ. Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2001;2:110-19
   PubMed Web of Science ®Google Scholar
• Tuschl T. RNA interference and small interfering RNAs. Chembiochem 2001;2:239-45
   PubMed Web of Science ®Google Scholar
• Ichim TE, Li M, Qian H, RNA interference: a potent tool for gene-specific therapeutics. Am J Transplant 2004;4:1227-36
   PubMed Web of Science ®Google Scholar
• Hannon GJ. RNA interference. Nature 2002;418:244-51
   PubMed Web of Science ®Google Scholar
• Hamilton AJ, Baulcombe DC. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 1999;286:950-2
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Harborth J, Lendeckel W, Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8
   PubMed Web of Science ®Google Scholar
• Kittler R, Buchholz F. RNA interference: gene silencing in the fast lane. Semin Cancer Biol 2003;13:259-65
   PubMed Web of Science ®Google Scholar
• Lu PY, Xie FY, Woodle MC. siRNA-mediated antitumorigenesis for drug target validation and therapeutics. Curr Opin Mol Ther 2003;5:225-34
   PubMed Web of Science ®Google Scholar
• Wall NR, Shi Y. Small RNA: can RNA interference be exploited for therapy? Lancet 2003;362:1401-3
   PubMed Web of Science ®Google Scholar
• Chen LM, Le HY, Qin RY, Reversal of the phenotype by K-rasval12 silencing mediated by adenovirus-delivered siRNA in human pancreatic cancer cell line Panc-1. World J Gastroenterol 2005;11:831-8
   PubMed Web of Science ®Google Scholar
• Wang YH, Liu S, Zhang G, Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 2005;7:220-8
   PubMed Web of Science ®Google Scholar
• Shen HL, Xu W, Wu ZY, Vector-based RNAi approach to isoform-specific down regulation of vascular endothelial growth factor (VEGF)165 expression in human leukemia cells. Leuk Res 2006;31:515-21
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang X, Bai CX, Inhibition of epidermal growth factor receptor expression by RNA interference in A549 cells. Acta Pharmacol Sin 2004;25:61-7
   PubMed Web of Science ®Google Scholar
• Yano J, Hirabayashi K, Nakagawa S, Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res 2004;10:7721-6
   PubMed Web of Science ®Google Scholar
• Gagnon V, Mathieu I, Sexton E, AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 2004;94:785-95
   PubMed Web of Science ®Google Scholar
• Duxbury MS, Ito H, Zinner MJ, siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. J Am Coll Surg 2004;198:953-9
   PubMed Web of Science ®Google Scholar
• Yamato K, Fen J, Kobuchi H, Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA. Cancer Gene Ther 2006;13:234-41
   PubMed Web of Science ®Google Scholar
• Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 2002;21:6041-8
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001;15:188-200
   PubMed Web of Science ®Google Scholar
• Zheng JN, Ma TX, Cao JY, Knock down of Ki-67 by small interfering RNA leads to inhibition of proliferation and induction of apoptosis in human renal carcinoma cells. Life Sci 2006;78:724-9
   PubMed Web of Science ®Google Scholar
• Zheng JN, Sun YF, Pei DS, Rapid inhibition of human renal carcinoma cells proliferation by anti-telomerase small-interfering RNAs. Acta Biochim Biophys Sin 2006;38:500-6
   Google Scholar
• Ailyn C, Patricia P, Tiffany H, siRNA targeting the IRF2 transcription factor inhibits leukaemic cell growth. Int J Oncol 2008;33:175-83
   PubMed Web of Science ®Google Scholar
• Jang JY, Choi Y, Jeon YK, Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Cancer Res 2008;10:11
   Web of Science ®Google Scholar
• Zhang YA, Nemunaitis J, Samuel SK, Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res 2006;66:9736-43
   PubMed Web of Science ®Google Scholar
• Lieskovan SH, Heidel JD, Bartlett DW, Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005;65:8984-92
   PubMed Web of Science ®Google Scholar
• Bartlett DW, Davis ME. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Bioeng 2007;97:909-21
   PubMed Web of Science ®Google Scholar
• Heidel JD, Yu Z, Liu JY, Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Nat Acad Sci USA 2007;104:5715-21
   PubMed Web of Science ®Google Scholar
• Bartlett DW, Davis ME. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol Bioeng 2007;99:975-85
   Web of Science ®Google Scholar
• Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008;18:305-19
   PubMed Web of Science ®Google Scholar
• Gondi CS, Rao JS. Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol 2009;220:285-91
   PubMed Web of Science ®Google Scholar
• Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 2009;10:850-62
   Google Scholar
• Lin X, Ruan X, Anderson MG, siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res 2005;33:4527-35
   PubMed Web of Science ®Google Scholar
• Fougerolles AD, Vornlocher HP, Maraganore J, Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007;6:443-53
   PubMed Web of Science ®Google Scholar
• Bumcrot D, Manoharan M, Koteliansky V, RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006;2:711-19
   PubMed Web of Science ®Google Scholar
• Sledz CA, Holko M, de Veer MJ, Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5:834-9
   PubMed Web of Science ®Google Scholar
• Bridge AJ, Pebernard S, Ducraux A, Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003;34:263-4
   PubMed Web of Science ®Google Scholar
• Hornung V, Guenthner-Biller M, Bourquin C, Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005;11:263-70
   PubMed Web of Science ®Google Scholar
• Kim DH, Longo M, Han Y, Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 2004;22:321-5
   PubMed Web of Science ®Google Scholar
• Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003;115:209-16
   PubMed Web of Science ®Google Scholar
• Lieberman J, Song E, Lee SK, Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends Mol Med 2003;9:397-403
   PubMed Web of Science ®Google Scholar
• Novina CD, Sharp PA. The RNAi revolution. Nature 2004;430:161-4
   PubMed Web of Science ®Google Scholar
• Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003;327:761-6
   PubMed Web of Science ®Google Scholar
• Tan Y, Zhang JS, Huang L. Codelivery of NF-kappaB decoy-related oligodeoxynucleotide improves LPD-mediated systemic gene transfer. Mol Ther 2002;6:804-12
   PubMed Web of Science ®Google Scholar
• Zhu H, Guo W, Zhang L, Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther 2005;4:451-6
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8
   PubMed Web of Science ®Google Scholar
• Xia H, Mao Q, Paulson HL, siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002;20:1006-10
   PubMed Web of Science ®Google Scholar
• Urban KB, Werth S, Abuharbeid S, RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005;12:461-6
   PubMed Web of Science ®Google Scholar
• Duan Y, Yang C, Zhang Z, Poly(ethylene glycol)-grafted polyethylenimine modified with G250 monoclonal antibody for tumor gene therapy. Hum Gene Ther 2010;21:191-8
   PubMed Web of Science ®Google Scholar
• Pan QW, Liu BS, Liu J, Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC. Acta Oncologica 2008;47:135-44
   PubMed Web of Science ®Google Scholar
• Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3
   PubMed Web of Science ®Google Scholar
• Barton GM, Medzhitov R. Retroviral delivery of small interfering RNA into primary cells. Proc Natl Acad Sci USA 2002;99:14943-5
   PubMed Web of Science ®Google Scholar
• Gu W, Putral L, Hengst K, Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther 2006;13:1023-32
   PubMed Web of Science ®Google Scholar
• Uchida H, Tanaka T, Sasaki K, Adenovirus-mediated transfer of siRNA against surviving induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 2004;10:162-71
   PubMed Web of Science ®Google Scholar
• Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic platform. Lancet Oncol 2002;3:17-26
   PubMed Web of Science ®Google Scholar
• Vecil GG, Lang FF. Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J Neurooncol 2003;65:237-46
   PubMed Web of Science ®Google Scholar
• Bischoff JR, Kirn DH, Williams A, An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6
   PubMed Web of Science ®Google Scholar
• Chu L, Gu J, Sun L, Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil. Gene Ther 2008;15:484-94
   PubMed Web of Science ®Google Scholar
• Carette JE, Overmeer RM, Schagen FH, Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cells. Cancer Res 2004;64:2663-7
   PubMed Web of Science ®Google Scholar
• Shiina M, Lacher MD, Christian C, RNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenoviruses. Cancer Gene Ther 2009;16:810-19
   PubMed Web of Science ®Google Scholar
• Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of Phase I and II trials. Expert Opin Biol Ther 2001;1:525-38
   PubMed Web of Science ®Google Scholar
• Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007;7:141-8
   PubMed Web of Science ®Google Scholar
• Curtin JF, Candolfi M, Xiong W, Turning the gene tap off; implications of regulating gene expression for cancer therapeutics. Mol Cancer Ther 2008;7:439-48
   PubMed Web of Science ®Google Scholar
• Nemunaitis BJ, Khuri F, Ganly I, Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus,in patients with refractory head and neck cancer. J Clin Oncol 2001;19:289-98
   PubMed Web of Science ®Google Scholar
• Ries S, Korn WM. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer 2002;86:5-11
   PubMed Web of Science ®Google Scholar
• Han ZQ, Assenberg M, Liu BL, Development of a second-generation oncolytic herpes simplex virus expressing TNFalpha for cancer therapy. J Gene Med 2007;9:99-106
   PubMed Web of Science ®Google Scholar
• Sauthoff H, Pipiya T, Heitner S, Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum Gene Ther 2002;13:1859-71
   PubMed Web of Science ®Google Scholar
• Pei Z, Chu L, Zou W, An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 2004;39:1371-81
   PubMed Web of Science ®Google Scholar
• Dong F, Wang L, Davis JJ, Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus. Clin Cancer Res 2006;12:5224-30
   PubMed Web of Science ®Google Scholar
• Guo W, Fang BL. Potentiation of oncolytic virotherapy with armed shRNA. Cancer Biol Ther 2009;8:1-2
   Google Scholar
• Lee YS, Kim JH, Choi KJ, Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res 2006;12:5859-68
   PubMed Web of Science ®Google Scholar
• Choi KJ, Kim JH, Lee YS, Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther 2006;13:1010-20
   PubMed Web of Science ®Google Scholar
• Zhao L, Gu J, Dong A, Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 2005;16:845-58
   PubMed Web of Science ®Google Scholar
• Ren Z, Ye X, Fang C, Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response. Cancer Biol Ther 2008;7:191-5
   PubMed Web of Science ®Google Scholar
• Han ZQ, Assenberg M, Liu BL, Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy. J Gene Med 2007;9:99-106
   PubMed Web of Science ®Google Scholar
• Wang ZG, Zhao W, Ramachandra M, An oncolytic adenovirus expressing soluble transforming growth factor-beta type II receptor for targeting breast cancer: in vitro evaluation. Mol Cancer Ther 2006;5:367-73
   PubMed Web of Science ®Google Scholar
• Yoo JY, Kim JH, Kwon YG, VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther 2007;15:295-302
   PubMed Web of Science ®Google Scholar
• Jakubczak JL, Ryan P, Gorziglia M, An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 2003;63:1490-9
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Cunningham C, Tong AW, Pilot trial of introvenous infusion of a replication-selective adenovirus (ONYX-015) in conbination with chemotherapy or IL-2 treastment in refractory cancer patients. Cancer Gene Ther 2003;10:341-52
   PubMed Web of Science ®Google Scholar
• Lin E, Nemunaitis J. Oncolytic viral therapies. Cancer Gene Ther 2004;11:643-64
   PubMed Web of Science ®Google Scholar
• Kim J, Kim JH, Choi KJ, E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Hum Gene Ther 2007;18:773-86
   PubMed Web of Science ®Google Scholar
• Yoo JY, Kim JH, Kim J, Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Ther 2008;15:635-51
   PubMed Web of Science ®Google Scholar
• Kang YA, Shin HC, Yoo JY, Novel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adeno-virus. Mol Ther 2008;16:1033-40
   PubMed Web of Science ®Google Scholar
• Zheng JN, Pei DS, Sun FH, Inhibition of renal cancer cell growth by oncolytic adenovirus armed short hairpin RNA targeting hTERT gene. Cancer Biol Ther 2009;8:84-91
   PubMed Web of Science ®Google Scholar
• Shen W, Wang CY, Wang XH, Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo. J Exp Clin Cancer Res 2009;28:81
   Web of Science ®Google Scholar
• Zheng JN, Pei DS, Mao LJ, Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA. Cancer Gene Ther 2009;16:20-32
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang H, Zhang J, Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors. Mol Ther 2009;17:57-64
   Google Scholar
• Tong AW, Zhang YA, Nemunaitis J. Small interfering RNA for experimental cancer therapy. Curr Opin Mol Ther 2005;7:114-24
   PubMed Web of Science ®Google Scholar
• Ter Brake O, 't Hooft K, Liu YP, Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther 2008;16:557-64
   PubMed Web of Science ®Google Scholar
• Gondi CS, Lakka SS, Dinh DH, Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biol 2004;1:165-76
   PubMed Web of Science ®Google Scholar
• Chen SM, Wang Y, Xiao BK, Effect of blocking VEGF, hTERT and Bcl-xl by multiple shRNA expression vectors on the human laryngeal squamous carcinoma xenograft in nude mice. Cancer Biol Ther 2008;7:734-9
   PubMed Web of Science ®Google Scholar
• Amarsanaa J, Fumihiko K, Hideaki I, Single small-interfering RNA expression vector for silencing multiple transforming growth factor-beta pathway components. Nucleic Acids Res 2005;33:e131
   PubMedGoogle Scholar
• Robson T, Hirst DG. Transcriptional targeting in cancer gene therapy. J Biomed Biotechnol 2003;2:110-37
   Google Scholar
• Sadeghi H, Hitt MM. Transcriptionally targeted adenovirus vectors. Curr Gene Ther 2005;5:411-27
   PubMed Web of Science ®Google Scholar
• Kanerva A, Hemminki A. Modified adenovirus for cancer gene therapy. Int J Cancer 2004;110:475-80
   PubMed Web of Science ®Google Scholar
• Tamar JG, Susan C, James TK. Rational design of a super core promoter that enhances gene expression. Nat Methods 2006;3:917-22
   PubMed Web of Science ®Google Scholar
• Shepard RN, Ornelles DA. E4orf3 is necessary for enhanced S-phase replication of cell cycle-restricted subgroup C adenoviruses. J Virol 2003;77:8593-5
   PubMed Web of Science ®Google Scholar
• Wang Y, Gangeswaran R, Zhao X, CEACAM6 attenuates adenovirus infection by antagonizing viral trafficking in cancer cells. J Clin Invest 2009;119:1604-15
   Google Scholar
• Dmitriev I, Krasnykh V, Miller CR, An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706-13
   PubMed Web of Science ®Google Scholar
• Rocconi RP, Zhu ZB, Stoff-Khalili M, Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd). Gynecol Oncol 2007;105:113-21
   PubMed Web of Science ®Google Scholar